Back to Search
Start Over
High prolactin levels in dihydropteridine reductase deficiency: A sign of therapy failure or additional pathology?
- Source :
-
JIMD reports [JIMD Rep] 2021 Jun 29; Vol. 61 (1), pp. 48-51. Date of Electronic Publication: 2021 Jun 29 (Print Publication: 2021). - Publication Year :
- 2021
-
Abstract
- We report the case of a 22-year-old man with a diagnosis of dihydropteridine reductase (DHPR) deficiency who progressively developed movement disorders and epilepsy. Despite L-Dopa supplementation the patient continued to show high prolactin levels, with a discrepancy between the neurological clinical picture and the hormonal biochemical levels. For this reason, other potential causes were ruled out by performing a cerebral magnetic resonance imaging, which demonstrated a solid lesion in the pituitary gland strongly suggestive of a prolactinoma. As the association between metabolic disorders affecting biogenic amine synthesis and prolactinoma has not been previously reported in humans, this report suggests that a critical evaluation of the use of prolactin as a guide for therapy dosage should be made in patients with DHPR deficiency disorders.<br />Competing Interests: The authors declare that they have no conflict of interest.<br /> (© 2021 The Authors. JIMD Reports published by John Wiley & Sons Ltd on behalf of SSIEM.)
Details
- Language :
- English
- ISSN :
- 2192-8304
- Volume :
- 61
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- JIMD reports
- Publication Type :
- Report
- Accession number :
- 34485017
- Full Text :
- https://doi.org/10.1002/jmd2.12236